**ABSTRACT**

Fibroadenoma is a common abnormality which every surgeon has been exposed to, and there are several international guidelines regarding its management. However giant fibroadenomas, especially in the premenarche setting has been a rare occurrence, even for the experienced surgeon. Various reports have shown that we need to treat this condition more aggressively than the normal fibroadenoma, and issues of cosmesis in a developing breast along with the aim to preserve lactation functionality becomes an issue. Since these cases remain a single life time experience for most surgeons, there is a sparsity of treatment protocols even in literature. Through this paper we hope to shed some valuable insight to this rare disorder and help surgeon colleagues, when dealing with similar cases.

**Keywords:** Fibroadenoma, Giant, Premenarche, Bilateral, Breast

**INTRODUCTION**

Fibroadenomas are the commonest breast lumps encountered in young women accounting for 70% to 95% of breast biopsies, Neinstein et al reported fibroadenoma involving 68.3% of breast lumps in women less than 22 years, autopsies have shown an incidence of 15 to 23% and epidemiologic studies an incidence of 2.2 %. Giant fibroadenoma are rare, constituting about 4% and a further subtype the giant juvenile fibroadenoma constitutes only 0.5%. There are only a handful reports of bilateral giant juvenile fibroadenoma in adolescent females and it is more uncommon in premenarche girls. Our review focuses on premenarche bilateral giant fibroadenomas; presently due to its rarity there is no data about its population incidence, prevalence and management protocols.

Clinical scenarios have proved that this entity is more complex than previously imagined and a multi departmental team is required for most cases.

**METHODS**

We did a Pubmed and Medline search in January 2020 with the search words ‘fibroadenoma’ ‘giant’ ‘juvenile’ ‘bilateral’ and got 12 articles. Inclusion criteria included: case reports or case series of bilateral giant juvenile fibroadenoma in premenarche girls. Articles were excluded in unilateral cases, postmenarche girls and articles which did not specify about the menarche. After screening 5 articles met our criteria, abstract to full text review of relevant articles was done and bibliography of relevant articles were reviewed for missed articles.

**Case report**

A 14 year premenarche girl presented with a rapidly increasing right breast lump which she noticed three months back. On presentation she had two lump of 10x7 cm and 4x1.7 cm on her right breast, the lumps were mobile, skin was not involved, nipple areolar complex was normal and there was no axillary lumps. Fine needle
aspiration cytology (FNAC) was consistent with a fibroadenoma. Ultrasound of bilateral breast and axilla was done but no other lumps were detected. All other routine investigations were normal and she had no known comorbid condition or familial syndrome. On surgery very little normal breast tissue was identified and the histopathological examination (HPE) was consistent with a giant fibroadenoma.

At 3 months follow up she presented with a similar lump over her left breast. Examinations and FNAC were consistent with a giant juvenile fibroadenoma. Excision biopsy was done and 3 lumps were removed largest, of which was a 6x6 cm lump (Figure 1). Wound healed without any complications and on follow up at 3 months she informed us that her periods have started.

**Figure 1: Three excised fibroadenoma specimen, largest 6 cm.**

**RESULTS**

Six cases were analysed: five publications plus our case report. All articles were from 2007 to 2017, five reports were from the Indian subcontinent and one from America. Age at presentation ranged between 9 to 14 years and predominant presenting complaint was lump with pain.

Duration of lump was between 2 to 12 months with an average of 5.6 months. Two patients had skin ulceration on presentation, in one patient both the nipple areola complex were destroyed.16,17 There were no known comorbidities/syndromes, no medical therapy was attempted before the surgery and no reconstruction was done. Majority of the reports had single giant fibroadenoma and some multiple fibroadenoma on one breast, only our patient had multiple bilateral fibroadenoma. The largest fibroadenoma was 22 cm in size and smallest 6 cm, with an average size of 12.7 cm on the right breast and 13.3 cm on the left breast. Heaviest fibroadenoma recorded was 950 gms.15 There was no recurrence till the time the case reports were published and no long term results of any of the reports are available. Patient characteristics are summarised in Table 1.

**DISCUSSION**

Fibroadenoma is a byproduct of lobular hyperplasia from a single lobule containing epithelial and stromal component.3 Definition of giant fibroadenoma has generally been considered as >5 cm, while some authors defines it as >500 g, or when replacing at least four-fifths of the breast tissue.3,18,19

In our review five out of the six reports are from the Indian subcontinent, but generally it has been considered that fibroadenomas are more common in the African population, this may simply be due to under reporting from the African nations or may be an actual occurrence.20,21 The picture will become clearer if more reports are published.

<table>
<thead>
<tr>
<th>Author</th>
<th>Country</th>
<th>Age (Y)</th>
<th>Duration (months)</th>
<th>Focality Single/Multiple</th>
<th>Size in cm</th>
<th>Surgery</th>
</tr>
</thead>
<tbody>
<tr>
<td>Moore 200717</td>
<td>USA</td>
<td>9</td>
<td>12</td>
<td>Single</td>
<td>17X15</td>
<td>18.5X16 b/l subtotal mastectomy</td>
</tr>
<tr>
<td>Mukhopadhyay 200916</td>
<td>India</td>
<td>11</td>
<td>2</td>
<td>Single</td>
<td>22X20</td>
<td>Excision</td>
</tr>
<tr>
<td>Nikumbh 201115</td>
<td>India</td>
<td>12</td>
<td>3</td>
<td>Single</td>
<td>15X12 (800 gms)</td>
<td>17X15 (950 gms)</td>
</tr>
<tr>
<td>Khan 201514</td>
<td>Pakistan</td>
<td>10</td>
<td>12</td>
<td>Single</td>
<td>6X5 (509 gms)</td>
<td>10X15 (754 gms)</td>
</tr>
<tr>
<td>Makkar 201713</td>
<td>India</td>
<td>14</td>
<td>2</td>
<td>Multiple</td>
<td>6X5</td>
<td>10X6 Excision</td>
</tr>
<tr>
<td>Raleng 2021</td>
<td>India</td>
<td>14</td>
<td>3</td>
<td>Multiple</td>
<td>10X7</td>
<td>6X6 Excision</td>
</tr>
</tbody>
</table>
Premenopausal bilateral giant juvenile fibroadenoma gives rise to some unique problems:

Patients with unilateral giant fibroadenoma can offer lactation later in life, but in bilateral giant fibroadenomas, if bilateral mastectomy were performed lactation is not possible. The sparsity of breast tissue might confuse surgeons regarding the extent of surgery, especially when there is suspicion for a phyllodes tumour. Since this concerns young women; though no studies have been done; cosmetic issues are of prime importance.

**Hormonal perspective**

It is known that breast development (thelarch) occurs about 2 years earlier than onset of periods in females (menarch), and the primary hormones responsible for breast development are estradiol; which influences ductal development; and progesterone stimulates lobular development. SAPINO et al studied specimens of fibroadenoma and phyllodes tumor, and found increased expression of estrogen receptor β, suggesting estrogen in the pathogenesis of these tumours. Later BRANCHINI et al found increased levels of progesterone receptors A and B in women with fibroadenomas, indication that progesterone and not estrogen receptors might be responsible.

WELSCH et al in 1979 suggested that prolactin levels might be related to fibroadenoma stimulation, since NICOL et al have showed high prolactin levels in a minor population of benign and malignant breast patients. Recent reports have suggested that it may be the increase expression of prolactin receptors in fibroadenomas and perhaps not the prolactin levels by itself. Steroid receptors may also play a role, owing to reports of fibroadenoma increasing in size during pregnancy and lactation, and its regression after menopause.

**Malignant transformation concerns**

DUPONT et al did a long term follow up in 1,835 patients and concluded that relative risk of invasive cancer is higher by 2.17 in patients with fibroadenomas. Other smaller series found malignant transformation of about 0.3%. Contrary to the above studies, NEISNITEIN et al after a longitudinal study in adolescent patients concluded prevalence of malignancies in fibroadenomas as practically 0%. CARTER after following up the same cohort of patients as DUPONT stated that there is no long term risk for malignancy in women with fibroadenomas containing atypias. Other reports have also confirmed that malignant transformation in fibroadenomas is not of significant clinical concern and remains a rare occurrence. Irrespective of what the literature says, for patients the fear of malignancy is one of their primary distress and this should be discussed in detailed with them. None of our reports have long term follow up results; we are yet to understand how it behaves in a giant fibroadenoma.

**Diagnosis**

Greatest diagnostic dilemma for a giant fibroadenoma is differentiating with phyllodes tumour, they have similar parameters on clinical, imaging, and histopathological examination. Phyllodes tumour occurs in 0.3 to 1% of breast tumors and though very rare in children, phyllodes tumour should always be considered as a differential diagnosis when dealing with a giant fibroadenoma. While fibroadenoma just needs simple excision, phyllodes tumour needs a more radical approach with a minimum of 1cm wide excision, and addition of adjuvant therapies.

Ultrasound currently is the preferred method of investigation in young girls for a breast lump. In a series of 115 pediatric patients Omar et al could accurately detect almost 98% of fibroadenomas with ultrasound, 3 patients which were missed had phyllodes tumour; all diagnosis were confirmed with excision and histopathological examination. DUMAN et al also suggested that ultrasound, mammogram and MRI could help differentiate between fibroadenoma and phyllodes tumour for tumours >3 cm, but YILMAZ et al reported that we cannot differentiate fibroadenoma from phyllodes tumour depending on their mammographic and ultrasound features, due to numerous overlap in image characteristics.

Core needle biopsy (CNB) is the established investigation for breast lumps suspicious for malignancies, because of its added benefits in evaluating the estrogen/progesterone receptor and Her-2 status. In a landmark article LAWTON et al showed that even experience pathologist who specialise in breast pathology struggle to distinguish between some cellular fibroadenoma and phyllodes tumour. For fibroadenomas SMITH et al showed that CNB did not add benefit in ladies less than 25 years, and FNAC should be the preferred choice. However, BODE et al evaluated 54 patients, with their excision biopsy results and concluded that CNB was able to differentiate between fibroadenoma and phyllodes tumour with some certainty; with false negative rate (FNR) of 17% for phyllodes tumour. Although FNR for fibroadenoma was 40% in that study, this was due to 33% showing other benign pathology. GATTA et al in a larger series confirmed that CNB had the highest sensitivity, specificity and positive predictive values (81%, 97% and 87% (p=0.001)) compared to mammography and ultrasound, in differentiating fibroadenoma from phyllodes tumour. The WHO 2012 criteria for phyllodes tumour was explored by CHANG et al, they found an increased diagnosis of benign phyllodes and a decrease in fibroadenoma after its use.

ADAMIETZ et al examined 123 lesions of fibroadenoma and 8 phyllodes tumour with real time elastography, they...
found that all phyllodes tumour had similar elastic pattern referred to as the "ring sign"; this was found in only 5% of fibroadenomas. In 2014 a larger retrospective data of 350 breast lesions were analyzed, they found a mean strain ratio of 3.19±2.33, 2.94±2.35 and 1.69±0.88 for malignant phyllodes, borderline phyllodes and fibroadenoma, suggesting that elastograph could help differentiate between fibroadenoma and phyllodes tumour.51

From these evidences in literature, we can conclude that, a multimodality imaging and core biopsy gives the best results, to differentiate between giant fibroadenomas and phylloide tumors.

**Genetics**

Koutselini et al first studied p53 in breast cells; 38 out of 39 (97.4%) benign breast tumors stained negative for p53.52 Franco et al in 2001 reported absence of TP53 mutations in fibroadenomas.53 Later Hodges et al in 2009 after analysing a case of synchronous fibroadenoma and phyllodes tumour, reported allelic loss at TP53 and D22S264, while Schneider et al found increased p53 gene in fibroadenoma specimens.54,55 The exact role of p53 in fibroadenomas is not well understood.

Cancer syndromes like Mafucci’s, Cowden’s syndrome and Carney complex are associated with multiple fibroadenomas, however no association with premenarch bilateral juvenile giant fibroadenomas have been proven yet.19

**Treatment**

Presently there is no consensus in the treatment of giant juvenile fibroadenomas, complete excision while preserving the developing breast and the nipple areola complex is the goal.56 Mastectomy in certain cases with or without reconstruction may be required; delayed reconstruction might be a better choice due to the recurrent nature of this disease.6,17 Since spontaneous regression is known to occur in 1% to 19% of FA, for lumps <5 cm watchful observation every 2-6 months for up to 2 years, is the protocol followed by many centers.2,57 Observation does not entail a casual approach, some bilateral giant fibroadenoma seems to have the capacity to grow rapidly; some patients in this series had massive growth within 2-3 months.13,15,16 If not treated in time they can give rise to challenging local complications, including nipple areola complex destruction or ulcerated growth mimicking breast cancer.17,22

**Tamoxifen**

Since estrogen is postulated in the development of fibroadenomas, tamoxifen a selective estrogen receptor modulator became the natural choice in its treatment. Chiu et al examined 13,203 patients from NSABP Breast

Cancer Prevention Trial and reported that tamoxifen reduces the risk for fibroadenomas (RR=0.77, 95% CI=0.56 to 1.04).58,59 Viviani et al did a randomised controlled trial and found that 20 mg tamoxifen/day for 50 days caused a reduction in fibroadenomas.60 In another randomised controlled trial, in premenopausal women and found that proliferative cell nuclear antigen, a marker of cell proliferation was reduced with 20 mg tamoxifen (p=0.031); however this study is criticized for a wide confidence interval (1.39-26.67).61 MIB-1 has also shown co-relation with tumor size, nodal metastasis, p53 overexpression, and an independent predictor of overall survival (RR 2.92, 95% CI 1.05-8.01, p<0.05), and disease free survival (RR 2.01, 95 CI 1.05-3.83, p<0.05) in breast cancers.62,63 In the randomized controlled trial done by De Sousa et al65 on fibroadenomas, there was significant reduction in MIB-1 with 10/20 mg tamoxifen, and reduction in PRL levels with 20mg tamoxifen (p=0.005).

Several studies from India has shown that centchroman (ormeloxifene) a nonsteroidal antiestrogen drug can promote complete regression in 31 to 40% fibroadenomas, but its role in giant juvenile fibroadenomas not clear so far.57,66

**Novel techniques**

Kitamura introduced the technique of endoscopy-assisted breast surgery (EABS) for benign breast tumors in 1998.67 In 2016 the Taiwan Endoscopic Breast Surgery Cooperative Group reported their experience, a total of 315 EABS procedures for breast cancers were performed between 2009 and 2014, with positive surgical margin rate of 1.9%.68 In 2017, Lai et al reported EABS in benign breast tumors, 323 EABS procedures were performed, the mean tumor size was 2.2 cm, with overall minor complications rate of 6.5%. Out of 110 patients 85.4% reported being satisfied with the cosmetic result.59 The only endoscopic publication for giant fibroadenomas are by Cheng et al, they published a 3 case report, the fibroadenomas ranged from 5 to 10 cm all were extracted with the help of an endoscope through a 1.5 to 4 cm preiareolar incision.70 The above reports suggest that EABS/robotic surgery is a possibility for selected giant fibroadenomas and they will provide the advantage of good cosmesis which is an added advantage for young girls.

Angio embolisation to shrink the tumour, has also been tried for huge bilateral giant juvenile fibroadenomas, more reports will be needed before we can validate its use routinely.7

**CONCLUSION**

Premenarche bilateral giant juvenile fibroadenomas needs to be treated speedily and aggressively, diagnosis whenever applicable should be with CNB and multimodal imaging. Wide excision should be the
primary form of treatment, delayed reconstruction in consultation with plastic surgeons is a sensible choice. Tamoxifen if contemplated should be initiated early, for best results. Patient and parents needs proper counselling regarding body image issues and expectation of cosmetic surgery.

**Funding:** No funding sources

**Conflict of interest:** None declared

**Ethical approval:** Not required

**REFERENCES**


